Femasys (NASDAQ:FEMY) Stock Price Down 3.2% – Here’s Why

Femasys Inc. (NASDAQ:FEMY) shares dropped 3.2% during trading on Monday . The company traded as low as $1.17 and last traded at $1.20. Approximately 85,253 shares were traded during mid-day trading, a decline of 64% from the average daily volume of 237,423 shares. The stock had previously closed at $1.24.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Femasys in a research note on Friday, March 28th.

Femasys Price Performance

The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26. The business’s 50 day moving average price is $1.41 and its 200 day moving average price is $1.23. The stock has a market capitalization of $32.58 million, a P/E ratio of -1.48 and a beta of -2.55.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. The firm had revenue of $0.58 million for the quarter, compared to analysts’ expectations of $1.66 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. Sell-side analysts forecast that Femasys Inc. will post -0.86 EPS for the current year.

Institutional Investors Weigh In On Femasys

Several institutional investors have recently modified their holdings of FEMY. XTX Topco Ltd raised its holdings in Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after buying an additional 18,004 shares during the period. Geode Capital Management LLC raised its stake in shares of Femasys by 9.2% in the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after acquiring an additional 17,473 shares during the period. Virtu Financial LLC bought a new stake in shares of Femasys in the 4th quarter worth about $25,000. Northern Trust Corp boosted its stake in shares of Femasys by 42.6% during the 4th quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after purchasing an additional 37,675 shares during the period. Finally, Jane Street Group LLC bought a new position in Femasys during the 4th quarter valued at about $30,000. 65.27% of the stock is owned by institutional investors.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.